Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Share Holder Update

Category: News & Announcements 2018By Richard Mollard July 31, 2018

Related posts

Top 20 Shareholders 30th December 2018
January 7, 2019

Top 20 Shareholders 14 December 2018
December 17, 2018

PharmAust Manufacturing Method Maintains Drug Potency
December 2, 2018

GMP Tablet Production for Clinical Trials Commences
November 13, 2018

2018 AGM Results
November 9, 2018

2018 AGM Presentation
November 9, 2018

Recent Articles

31 January 2020, Top 20 Shareholders
January 31, 2020
28 January, Appendix 4C and Quarterly Update
January 28, 2020
$700K R&D Tax Incentive Refund.
January 14, 2020
Epichem Awarded DNDi Contract Extension
January 8, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. ASX: $PAA

PharmAust @PharmAust·

Animal Healthcare Market Size Worth US$ 177.1 Billion by 2026 https://www.prnewswire.com/news-releases/animal-healthcare-market-size-worth-us-177-1-billion-by-2026--301000272.html

Reply on Twitter 1225444110309347331 Retweet on Twitter 12254441103093473311 Like on Twitter 12254441103093473313 Twitter 1225444110309347331

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions